Prudential Financial Inc Mei Pharma, Inc. Transaction History

Prudential Financial Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.22 - $8.4 $15,224 - $581,280	69,200 Added 89.64%	146,400 $0
Q3 2022 Nov 04, 2022	BUY	$0.41 - $8.8 $31,651 - $679,360	77,200 New	77,200 $30,000
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $238,767 - $369,521	-568,495 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$0.54 - $2.74 $306,987 - $1.56 Million	568,495 New	568,495 $343,000
Q3 2021 Nov 15, 2021	SELL	$2.52 - $2.99 $34,168 - $40,541	-13,559 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.6 - $3.65 $364 - $511	140 Added 1.04%	13,559 $39,000
Q1 2021 May 12, 2021	BUY	$2.73 - $4.5 $6,926 - $11,416	2,537 Added 23.31%	13,419 $46,000
Q4 2020 Feb 16, 2021	BUY	$2.6 - $3.32 $910 - $1,162	350 Added 3.32%	10,882 $29,000
Q3 2020 Nov 16, 2020	SELL	$2.46 - $4.27 $139,632 - $242,369	-56,761 Reduced 84.35%	10,532 $33,000
Q1 2020 May 12, 2020	BUY	$0.75 - $2.55 $39,264 - $133,500	52,353 Added 350.42%	67,293 $108,000
Q4 2019 Feb 11, 2020	BUY	$1.65 - $2.48 $4,595 - $6,906	2,785 Added 22.91%	14,940 $37,000
Q3 2019 Nov 13, 2019	BUY	$1.48 - $2.52 $17,989 - $30,630	12,155 New	12,155 $20,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $370M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.